Imperva Inc (NYSE:IMPV) had its target price reduced by Imperial Capital from $57.00 to $50.00 in a research report report published on Tuesday morning, Marketbeat.com reports. They currently have an outperform rating on the software maker’s stock.
A number of other brokerages have also recently weighed in on IMPV. BidaskClub cut Imperva from a strong-buy rating to a buy rating in a report on Wednesday, July 5th. ValuEngine cut Imperva from a hold rating to a sell rating in a report on Tuesday, July 11th. Stephens reissued an overweight rating and set a $61.00 price objective (up from $53.00) on shares of Imperva in a report on Thursday, July 13th. Stifel Nicolaus reissued a hold rating and set a $47.00 price objective on shares of Imperva in a report on Friday, July 14th. Finally, Evercore ISI set a $56.00 price objective on Imperva and gave the company a buy rating in a report on Friday, July 28th. One investment analyst has rated the stock with a sell rating, ten have given a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of Hold and an average price target of $52.34.
Imperva (NYSE IMPV) traded up 0.287% on Tuesday, reaching $43.625. The company’s stock had a trading volume of 54,684 shares. The stock’s 50 day moving average price is $44.05 and its 200 day moving average price is $45.81. Imperva has a 52-week low of $34.40 and a 52-week high of $52.40. The firm’s market cap is $1.48 billion.
Imperva (NYSE:IMPV) last released its quarterly earnings results on Thursday, July 27th. The software maker reported ($0.10) earnings per share for the quarter, missing the consensus estimate of $0.05 by ($0.15). Imperva had a negative net margin of 4.69% and a negative return on equity of 5.00%. The business had revenue of $74.44 million during the quarter, compared to analysts’ expectations of $74.30 million. During the same period in the previous year, the business earned ($0.23) EPS. The business’s revenue was up 28.6% on a year-over-year basis. Equities research analysts expect that Imperva will post $0.81 earnings per share for the current fiscal year.
In related news, Director Anthony J. Bettencourt sold 99,598 shares of the firm’s stock in a transaction that occurred on Thursday, August 24th. The stock was sold at an average price of $43.59, for a total transaction of $4,341,476.82. Following the transaction, the director now directly owns 99,598 shares in the company, valued at approximately $4,341,476.82. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 2.20% of the stock is owned by company insiders.
Hedge funds have recently modified their holdings of the company. Ameritas Investment Partners Inc. bought a new stake in shares of Imperva in the 1st quarter worth approximately $102,000. Migdal Insurance & Financial Holdings Ltd. grew its position in shares of Imperva by 26.2% in the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 4,177 shares of the software maker’s stock worth $201,000 after buying an additional 866 shares during the last quarter. Amalgamated Bank bought a new stake in shares of Imperva in the 2nd quarter worth approximately $206,000. Principal Financial Group Inc. bought a new stake in shares of Imperva in the 2nd quarter worth approximately $223,000. Finally, KCG Holdings Inc. bought a new stake in shares of Imperva in the 1st quarter worth approximately $201,000. Hedge funds and other institutional investors own 92.72% of the company’s stock.
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with MarketBeat.com's FREE daily email newsletter.